Chemical Namebictegravir, embitcitabine, and tenofovir alafenamide
Dosage FormTablet (oral; 50 mg bictegravir (equivalent to 52.5 mg bictegravir sodium), 200 mg emtricitabine, and 25 mg tenofovir alafenamide (equivalent to 28 mg tenofovir alafenamide fumarate)
Drug ClassAntivirals
CompanyGilead Sciences Inc.
Approval Year2018


  • Biktarvy is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of BIKTARVY.
Last updated on 10/22/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?